We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Knee-Tensioning Device Relieves Arthritic Knee Pain

By HospiMedica International staff writers
Posted on 03 Mar 2010
A novel knee biomechanical dosing system allows a patient to adjust precisely the amount of pain-relieving force applied to an osteoarthritic (OA) knee.

The Bellacure treatment device is a noninvasive, visually discreet device worn against the skin that gives patients the ability to apply reproducibly a therapeutic force known as the valgus moment, which urges the femur and tibia apart on the affected side of the OA knee. More...
The force application efficiency is achieved by using a cable tensioning system that creates a true three-point-force system, where nearly 100% of the force developed by the device contributes to the therapeutic effect, namely the relief of OA knee pain. The cables automatically set to the proper initial length, matching the patient's unique anatomy, thus maximizing force efficiency and minimizing weight at a high pain-relief intensity level.

The device, which is worn around the knee, is made up of a lightweight, high stretch, and breathable outer fabric structure that conceals the integrated mechanical elements, allowing the patient to receive consistent pain relief. Once the device is pulled up the leg and positioned around the knee, the patient simply engages and rotates the dosing mechanism until the prescribed pain-relief level is attained. Patients can choose to release the applied pressure or change the dosage in one-step without removing the device.

The dosing mechanism is comprised of four independent microcables, which automatically adjust themselves to the patient's leg diameter. After the device is pulled into place, the patient engages the dosing cap by pressing in toward the leg until the dial snaps into place, and then simply rotates the cap to apply the dose. The dosing mechanism presses against an air bladder to distribute pressure comfortably around the knee. The Bellacure treatment device was developed by Bellacure (Seattle, WA, USA), and has been awarded a patent by the U.S. Patent Office.

"Advancements in biomechanics, microelectronics, micromechanics, and the technical garment industry have enabled us to produce an arthritis treatment device that is efficient and effective,” said Shane Sterling, CEO of Bellacure. "I think the greatest achievement we've made with the Bellacure treatment device is how all this technology is transparent and easy for the patient to use. Our goal is to provide the arthritic pain relief patients need to seamlessly maintain or return to their previous lifestyles.”

Related Links:

Bellacure



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.